Purandare A S, Smith D S, Wilson P J
Wessex Regional Transfusion Centre, Southampton, England.
Int J Fertil Menopausal Stud. 1993 Jul-Aug;38(4):219-24.
To test couples with three or more consecutive recurrent miscarriages for suitability of the mother for immunization with paternal lymphocytes.
Regional transfusion centre, patients referred by local obstetricians.
Women treated were from 103 couples with > or = 3 consecutive recurrent miscarriages and no more than one live birth. HLA sharing and frequencies were investigated, and contrasted with control data. Patients showed increased sharing versus control (but not in comparison with gene frequencies of the county population). Sixty-eight mothers were finally found suitable and immunized with paternal lymphocytes.
Pregnancy and live births.
55/68 conceived, with 30 live births resulting; 8/13 additional successes after repeat (booster) immunization.
This treatment still suffers from the lack of clear criteria for patient selection, and it should be submitted to a prospective controlled double-blind trial.
对有三次或三次以上连续复发性流产的夫妇进行检测，以确定母亲是否适合用父亲的淋巴细胞进行免疫治疗。
地区输血中心，由当地产科医生转诊的患者。
接受治疗的女性来自103对夫妇，这些夫妇有三次或三次以上连续复发性流产且活产不超过一次。对人类白细胞抗原（HLA）的共享情况和频率进行了调查，并与对照数据进行了对比。与对照组相比，患者显示出更高的HLA共享率（但与该县人群的基因频率相比无差异）。最终发现68名母亲适合并接受了父亲淋巴细胞免疫治疗。
妊娠和活产情况。
68名母亲中有55名怀孕，共分娩30名活产婴儿；13名经重复（加强）免疫治疗后有8名获得成功。
这种治疗方法仍然缺乏明确的患者选择标准，应进行前瞻性对照双盲试验。
